International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 37

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7): 1969. **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996.*

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMENDÉES (DCI Rec): Liste 37

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969. **173**, 10 (résolution EB43 R9)] les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996.*

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 37

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996.*

MODIFICATION

This is to inform you that WHO will henceforth publish lists of recommended INNs **twice a year.**

This new measure is intended to provide information as soon as possible on the names that have reached the status of recommended INNs.

MODIFICATION

L'OMS publiera désormais les listes des DCI recommandées **deux fois par an**.

Cette nouvelle mesure est destinée à informer les lecteurs dès que possible au sujet des dénominations ayant atteint le statut de DCI recommandée.

MODIFICACION

De ahora en adelante, la OMS publicará **dos veces por año** las listas de DCI recomendadas.

Con esta nueva medida se quiere facilitar lo antes posible la información sobre las denominaciones a las que se ha asignado la condición de DCI recomendadas.

Latin, English, French, Spanish *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

agomelatinum

agomelatine — *N*-[2-(7-methoxy-1-naphthyl)ethyl]acetamide

agomélatine — *N*-[2-(7-méthoxynaphtalén-1-yl)éthyl]acétamide

agomelatina — *N*-[2-(7-metoxi-1-naftil)etil]acetamida

$C_{15}H_{17}NO_2$



alatrofloxacinum

alatrofloxacin — 7-[(1*R*,5*S*,6*s*)-6-[(*S*)-2-[(*S*)-2-aminopropionamido]propionamido]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

alatrofloxacine — acide 7-[(1*R*,5*S*,6*s*)-6-[[(2*S*)-2-[[(2*S*)-2-aminopropanoyl]amino]propanoyl]=amino]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophényl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphtyridine-3-carboxylique

alatrofloxacino — ácido 7-[(1*R*,5*S*,6*s*)-6-[(*S*)-2-[(*S*)-2-aminopropionamido]propionamido]-3-azabiciclo[3.1.0]hex-3-il]-1-(2,4-difluorofenil)-6-fluoro-1,4-dihidro-4-oxo-1,8-naftiridina-3-carboxílico

$C_{26}H_{25}F_3N_6O_5$



aripiprazolum

aripiprazole — 7-[4-[4-(2.3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril

aripiprazole — 7-[4-[4-(2.3-dichlorophényl)pipérazin-1-yl]butoxy]-3,4-dihydroquinoléin-2(1*H*)-one

aripiprazol — 7-[4-[4-(2,3-diclorofenil)-1-piperazinil]butoxi]-3,4-dihidrocarbostiril

$C_{23}H_{27}Cl_2N_3O_2$



arofyllinum

arofylline — 3-(*p*-chlorophenyl)-1-propylxanthine

arofylline — 3-(4-chlorophényl)-1-propyl-3,7-dihydro-1*H*-purine-2,6-dione

arofilina — 3-(*p*-clorofenil)-1-propilxantina

$C_{14}H_{13}ClN_4O_2$



atiprimodum

atiprimod — 2-[3-(diethylamino)propyl]-8,8-dipropyl-2-azaspiro[4.5]decane

atiprimod — 3-[8,8-dipropyl-2-azaspiro[4 5]déc-2-yl]-*N,N*-diéthylpropan-1-amine

atiprimod — 2-[3-(dietilamino)propil]-8,8-dipropil-2-azaspiro[4.5]decano

$C_{22}H_{44}N_2$



bectumomabum

bectumomab — immunoglobulin G 2a (mouse monoclonal IMMU-LL2 Fab' fragment γ-chain anti-human antigen CD 22), disulfide with mouse monoclonal IMMU-LL2 light chain

bectumomab — immunoglobuline G 2a (chaîne γ du fragment Fab' de l'anticorps monoclonal de souris IMMU-LL2 anti-antigène CD 22 humain), disulfure avec la chaîne légère de l'anticorps monoclonal de souris IMMU-LL2

bectumomab — inmunoglobulina G 2a (cadena γ del fragmento Fab' del anticuerpo monoclonal de ratón IMMU-LL2 anti-antígeno CD 22 humano), disulfuro con la cadena ligera del anticuerpo monoclonal de ratón IMMU-LL2

beloxepinum

beloxepin — (±)-*cis*-1,3,4,13b-tetrahydro-2,10-dimethyldibenz[2.3:6,7]oxepino=[4,5-*c*]pyridin-4a(2*H*)-ol

béloxépine — (4a*RS*,13b*RS*)-2,10-diméthyl-1.3,4,13b-tétrahydrodibenzo[2,3:6,7]oxépino=[4,5-*c*]pyridin-4a(2*H*)-ol

beloxepina — (±)-*cis*-1,3,4.13b-tetrahidro-2.10-dimetildibenz[2.3 6,7]oxepino=[4,5-*c*]piridin-4a(2*H*)-ol

$C_{19}H_{21}NO_2$



and enantiomer
et l'énantiomère
y enantiómero

bemiparinum natricum

bemiparin sodium — Sodium salt of depolymerized heparin obtained by alkaline degradation of quaternary ammonium salt of heparin from pork intestinal mucosa; the majority of the components have a 2-*O*-sulfo-4-enepyranosuronic acid structure at the non-reducing end and a 2-*N*,6-*O*-disulfo-D-glucosamine structure at the reducing end of their chain; the average relative molecular mass is about 3600 (3000 to 4200); the degree of sulfatation is about 2 per disaccharidic unit.

bémiparine sodique — Sel de sodium d'héparine dépolymérisée obtenue par fragmentation alcaline d'un sel d'ammonium quaternaire d'héparine de muqueuse intestinale de porc. La majorité des composants présentent une structure acide 2-*O*-sulfo-4-ènepyranosuronique à l'extrémité non réductrice et une structure 2-*N*,6-*O*-disulfo-D-glucosamine à l'extrémité réductrice de leur chaîne. La masse moléculaire relative moyenne est voisine de 3600 (3000 à 4200). Le degré de sulfatation est voisin de 2 par unité disaccharide

bemiparina sódica

Sal de sodio de heparina despolimerizada obtenida por fragmentación alcalina de una sal de amonio cuaternario de heparina de mucosa intestinal de cerdo. La mayoría de los componentes presentan una estructura ácido 2-*O*-sulfo-4-enopiranosurónico en el extremo no reductor y una estructura 2-*N*,6-*O*-disulfo-D-glucosamina en el extremo reductor de su cadena. La masa molecular relativa media es aproximadamente 3600 (de 3000 a 4200). El grado de sulfatación es aproximadamente 2 por unidad de disacárido.

cemadotinum

cemadotin

N,*N*-dimethyl-L-valyl-L-valyl-*N*-methyl-L-valyl-L-prolyl-*N*-benzyl-L-prolinamide

cémadotine

(*N*,*N*-diméthyl-L-valyl)-L-valyl-(*N*-méthyl-L-valyl)-L-prolyl-(*N*-benzyl-L-prolinamide)

cemadotina

N,*N*-dimetil-L-valil-L-valil-*N*-metil-L-valil-L-prolil-*N*-bencil-L-prolinamida

$C_{35}H_{56}N_6O_5$



choriogonadotropinum alfa

choriogonadotropin alfa

human chorionic gonadotropin (protein moiety reduced), glycoform α
α-subunit:
chorionic gonadotropin (human α-subunit protein moiety reduced)
β-subunit:
chorionic gonadotropin (human β-subunit protein moiety reduced)

choriogonadotropine alfa

gonadotropine chorionique humaine (partie protéique réduite), forme glycosylée α
sous-unité α:
gonadotropine chorionique (partie protéique réduite de la sous-unité α humaine)
sous-unité β:
gonadotropine chorionique (partie protéique réduite de la sous-unité β humaine)

coriogonadotropina alfa

gonadotropina coriónica humana (fracción proteica reducida), glucoforma α
subunidad α:
gonadotropina coriónica (fracción proteica reducida de la subunidad α humana)
subunidad β:
gonadotropina coriónica (fracción proteica reducida de la subunidad β humana)

α: $C_{437}H_{682}N_{122}O_{134}S_{13}$

β: $C_{658}H_{1090}N_{196}O_{203}S_{13}$

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP
LRSKKTMLVQ KNVTSESTCC VAKSYNRVTV MGGFKVENHT
ACHCSTCYYH KS

SKEPLRPRCR PINATLAVEK EGCPVCITVN TTICAGYCPT
MTRVLQGVLP ALPQVVCNYR DVRFESIRLP GCPRGVNPVV
SYAVALSCQC ALCRRSTTDC GGPKDHPLTC DDPRFQDSSS
SKAPPPSLPS PSRLPGPSDT PILPQ

clevidipinum

clevidipine

(±)-hydroxymethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2.6-dimethyl-3,5-pyridinedicarboxylate, butyrate (ester)

clévidipine

(4*RS*)-4-(2,3-dichlorophényl)-2,6-diméthyl-1.4-dihydropyridine-3,5-dicarboxylate de butanoyloxyméthyle et de méthyle

clevidipino

(±)-4-(2,3-diclorofenil)-1,4-dihidro-2.6-dimetil-3,5-piridinadicarboxilato de butiriloximetilo y metilo

$C_{21}H_{23}Cl_2NO_6$



and enantiomer
et l'énantiomère
y enantiómero

domitrobanum

domitroban

(+)-(*Z*)-7-[(1*R*,2*S*,3*S*,4*S*)-3-benzenesulfonamido-2-norbornyl]-5-heptenoic acid

domitroban

acide (+)-(*Z*)-7-[(1*R*,2*S*,3*S*,4*S*)-3-[(phénylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]hept-5-énoique

domitrobán

ácido (+)-(Z)-7-[(1*R*,2S,3S,4S)-3-bencensulfonamido-2-norbornil]-5-heptenoico

$C_{20}H_{27}NO_4S$



donepezilum

donepezil (±)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-1-indanone

donépézil (2*RS*)-2-[(1-benzylpipéridin-4-yl)méthyl]-5,6-diméthoxy-2,3-dihydro-1*H*-indén-1-one

donepezilo (±)-2-[(1-bencil-4-piperidil)metil]-5,6-dimetoxi-1-indanona

$C_{24}H_{29}NO_3$



and enantiomer
et l'énantiomère
y enantiómero

dronedaronum

dronedarone *N*-[2-butyl-3-[*p*-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]=methanesulfonamide

dronédarone *N*-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]benzofuran-5-yl]méthanesulfonamide

dronedarona *N*-(2-butil-3-[*p*-[3-(dibutilamino)propoxi]benzoil]-5-benzofuranil]=metanosulfonamida

$C_{31}H_{44}N_2O_5S$



ecamsulum

ecamsule (±)-(3*E*,3'*E*)-3,3'-(*p*-phenylenedimethylidyne)bis[2-oxo-10-bornanesulfonic acid]

écamsule acide [[1,4-phénylènediméthylidyne]bis[(3*E*,3'*E*)-7,7-diméthyl-2-oxobicyclo[2.2 1]heptan-3,1-diyl]]diméthanesulfonique

ecamsul (±)-(3*E*,3'*E*)-3,3'-(*p*-fenilenodimetilidino)bis[ácido 2-oxo-10-bornanosulfónico]

$C_{28}H_{34}O_8S_2$



efepristinum

efepristin

N-[(6*R*,9*S*,10*R*,13*S*,15a*S*,22*S*,24a*S*)-6-ethyldocosahydro-10,23-dimethyl-22-[*p*-(methylamino)benzyl]-5,8,12,15,17,21,24-heptaoxo-13-phenyl-12*H*-pyrido[2,1-*f*]pyrrolo[2,1-*l*][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide

éfépristine

N-[(6*R*,9*S*,10*R*,13*S*,15a*S*,22*S*,24a*S*)-6-éthyl-10,23-diméthyl-22-[4-(méthylamino)benzyl]-5,8,12,15,17,21,24-heptaoxo-13-phényldocosahydro-12*H*-pyrido[2,1-*f*]pyrrolo[2,1-*l*][1,4,7,10,13,16]oxapentaazacyclononadécén-9-yl]-3-hydroxypyridine-2-carboxamide

efepristina

N-[(6*R*,9*S*,10*R*,13*S*,15a*S*,22*S*,24a*S*)-6-etildocosahidro-10,23-dimetil-22-[*p*-(metilamino)bencil]-5,8,12,15,17,21,24-heptaoxo-13-fenil-12*H*-pirido[2,1-*f*]pirrolo[2,1-*l*][1,4,7,10,13,16]oxapentaazaciclononadecin-9-il]-3-hidroxipicolinamida

$C_{44}H_{52}N_8O_{10}$



elinafidum

elinafide

N,N '-[trimethylenebis(iminoethylene)]dinaphthalimide

élinafide

2,2'-[propane-1,3-diylbis(iminoéthylène)]bis[1*H*-benzo[*de*]isoquinoléine-1,3(2*H*)-dione]

elinafida

N,N '-[trimetilenobis(iminoetileno)]dinaftalimida

$C_{31}H_{28}N_4O_4$



filaminastum

filaminast — 3'-(cyclopentyloxy)-4'-methoxyacetophenone (*E*)-*O*-carbamoyloxime

filaminast — 1-[3-(cyclopentyloxy)-4-méthoxyphényl]éthanone (*E*)-*O*-carbamoyloxime

filaminast — 3'-(ciclopentiloxi)-4'-metoxiacetofenona (*E*)-*O*-carbamoiloxima

$C_{15}H_{20}N_2O_4$



flibanserinum

flibanserin — 1-[2-[4-(α,α,α-trifluoro-*m*-tolyl)-1-piperazinyl]ethyl]-2-benzimidazolinone

flibansérine — 1-[2-[4-[3-(trifluorométhyl)phényl]pipérazin-1-yl]éthyl]-1,3-dihydro-2*H*-benzimidazol-2-one

flibanserina — 1-[2-[4-(α,α,α-trifluoro-*m*-tolil)-1-piperazinil]etil]-2-benzimidazolinona

$C_{20}H_{21}F_3N_4O$



fludarabinum

fludarabine — 9-β-D-arabinofuranosyl-2-fluoroadenine

fludarabine — 9-(β-D-arabinofuranosyl)-2-fluoro-9*H*-purin-6-amine

fludarabina — 9-β-D-arabinofuranosil-2-fluoroadenina

$C_{10}H_{12}FN_5O_4$



fomivirsenum

fomivirsen

2'-deoxy-*P*-thioguanylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thioguanylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')- *P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thioguanylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thioguanylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxyguanosine

fomivirsen

2'-désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2 -désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxyguanosine

fomivirseno

2'-desoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-*P*-tiotimidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-2'-desoxiguanosina

$C_{204}H_{263}N_{63}O_{114}P_{20}S_{20}$

foropafantum

foropafant

3-[[[2-(dimethylamino)ethyl][4-(2,4,6-triisopropylphenyl)-2-thiazolyl]amino]=methyl]pyridine

foropafant

N,*N*-diméthyl-*N*'-[(pyridin-3-yl)méthyl]-*N*'-[4-[2,4,6-tris(1-méthyléthyl)=phényl]thiazol-2-yl]éthane-1,2-diamine

foropafant

3-[[[2-(dimetilamino)etil][4-(2,4,6-triisopropilfenil)-2-tiazolil]amino]=metil]piridina

$C_{28}H_{40}N_4S$



icopezilum

icopezil

3-[2-(1-benzyl-4-piperidyl)ethyl]-5,7-dihydro-6*H*-pyrrolo[3,2-*f*]-1,2-benzisoxazol-6-one

icopézil

3-[2-(1-benzylpipéridin-4-yl)éthyl]-5,7-dihydro-6*H*-pyrrolo[3,2-*f*]-1,2-benzisoxazol-6-one

icopezilo

3-[2-(1-bencil-4-piperidil)etil]-5,7-dihidro-6*H*-pirrolo[3,2-*f*]-1,2-benzisoxazol-6-ona

$C_{23}H_{25}N_3O_2$



ioflupanum (^{123}I)

ioflupane (^{123}I)

methyl 8-(3-fluoropropyl)-3β-(*p*-iodo-^{123}*I*-phenyl)-1α*H*,5α*H*-nortropane-2β-carboxylate

ioflupane (^{123}I)

(1*R*,2*S*,3*S*,5*S*)-8-(3-fluoropropyl)-3-[4-[^{123}*I*]iodophényl]-8-azabicyclo[3.2.1]octane-2-carboxylate de méthyle

ioflupano (^{123}I)

8-(3-fluoropropil)-3β-(*p*-iodo-^{123}*I*-fenil)-1α*H*,5α*H*-nortropano-2β-carboxilato de metilo

$C_{18}H_{23}F^{123}INO_2$



ivabradinum

ivabradine

3-[3-[[[(7*S*)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]=methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2*H*-3-benzazepin-2-one

ivabradine

3-[3-[[[(7*S*)-3,4-diméthoxybicyclo[4 2.0]octa-1,3,5-trién-7-yl]méthyl]=méthylamino]propyl]-7,8-diméthoxy-1,3,4,5-tétrahydro-2*H*-3-benzazépin-2-one

ivabradina

3-[3-[[[(7*S*)-3,4-dimetoxibiciclo[4.2.0]octa-1,3,5-trien-7-il]metil]metilamino]=propil]-1,3,4,5-tetrahidro-7,8-dimetoxi-2*H*-3-benzazepin-2-ona

$C_{27}H_{36}N_2O_5$



lagatidum

lagatide L-prolyl-L-valyl-L-threonyl-L-lysyl-L-prolyl-L-glutaminyl-D-alaninamide

lagatide L-prolyl-L-valyl-L-thréonyl-L-lysyl-L-prolyl-L-glutaminyl-D-alaninamide

lagatida L-prolil-L-valil-L-treonil-L-lisil-L-prolil-L-glutaminil-D-alaninamida

$C_{33}H_{58}N_{10}O_9$

H—Pro—Val—Thr—Lys—Pro—Gln—D-Ala—NH_2

landiololum

landiolol (-)-[(*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl *p*-[(*S*)-2-hydroxy-3-[[2-(4-morpholinecarboxamido)ethyl]amino]propoxy]hydrocinnamate

landiolol (-)-3-[4-[(2*S*)-2-hydroxy-3-[[2-[(morpholin-4-ylcarbonyl)amino]éthyl]amino]=propoxy]phényl]propanoate de [(4*S*)-2,2-diméthyl-1,3-dioxolan-4-yl]méthyle

landiolol *p*-[(*S*)-2-hidroxi-3-[[2-(4-morfolinacarboxamido)etil]amino]propoxi]=hidrocinnamato de (-)-[(*S*)-2,2-dimetil-1,3-dioxolan-4-il]metil

$C_{25}H_{39}N_3O_8$



lefradafibanum

lefradafiban (3*S*,5*S*)-5-[[[4'-(carboxyamidino)-4-biphenylyl]oxy]methyl]-2-oxo-3-pyrrolidineacetic acid, dimethyl ester

lefradafiban 2-[(3*S*,5*S*)-5-[[[4'-[imino[(méthoxycarbonyl)amino]méthyl]biphényl-4-yl]oxy]méthyl]-2-oxopyrrolidin-3-yl]acétate de méthyle

lefradafibán éster dimetílico del ácido(3*S*,5*S*)-5-[[[4'-(carboxiamidino)-4-bifenilil]oxi]metil]-2-oxo-3-pirrolidinacético

$C_{23}H_{25}N_3O_6$



marimastatum

marimastat (2*S*,3*R*)-3-[[(1*S*)-2,2-dimethyl-1-(methylcarbamoyl)propyl]carbamoyl]-2-hydroxy-5-methylhexanohydroxamic acid

marimastat (2*R*,3*S*)-*N*^{1}-[(1*S*)-2,2-diméthyl-1-(méthylcarbamoyl)propyl]-*N*^{4},3-dihydroxy-2-(2-méthylpropyl)butanediamide

marimastat ácido (2*S*,3*R*)-3-[[(1*S*)-2,2-dimetil-1-(metilcarbamoil)propil]carbamoil]-2-hidroxi-5-metilhexanohidroxámico

$C_{15}H_{29}N_3O_5$



maxacalcitolum

maxacalcitol (+)-(5*Z*,7*E*,20*S*)-20-(3-hydroxy-3-methylbutoxy)-9,10-secopregna-5,7,10(19)-triene-1α,3β-diol

maxacalcitol (+)-(5*Z*,7*E*)-(20*S*)-20-(3-hydroxy-3-méthylbutoxy)-9,10-sécoprégna-5,7,10(19)-triène-1α,3β-diol

maxacalcitol (+)-(5*Z*,7*E*,20*S*)-20-(3-hidroxi-3-metilbutoxi)-9,10-secopregna-5,7,10(19)-trieno-1α,3β-diol

$C_{26}H_{42}O_4$



mazokalimum

mazokalim — ethyl 5-[(3*S*,4*R*)-4-[(1,6-dihydro-6-oxo-3-pyridazinyl)oxy]-3-hydroxy-2,2,3-trimethyl-6-chromanyl]-1*H*-tetrazole-1-butyrate

mazokalim — 4-[5-[(3*S*,4*R*)-3-hydroxy-2,2,3-triméthyl-4-(6-oxo-1,6-dihydropyridazin-3-yloxy)-3,4-dihydro-2*H*-chromén-6-yl]-1*H*-tétrazol-1-yl]butanoate d'éthyle

mazokalim — 5-[(3*S*,4*R*)-4-[(1,6-dihidro-6-oxo-3-piridazinil)oxi]-3-hidroxi-2,2,3-trimetil-6-cromanil]-1*H*-tetrazol-1-butirato de etilo

$C_{23}H_{28}N_6O_6$



nifekalantum

nifekalant — 6-[[2-[(2-hydroxyethyl)[3-(*p*-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyluracil

nifékalant — 6-[[2-[(2-hydroxyéthyl)[3-(4-nitrophényl)propyl]amino]éthyl]amino]-1,3-diméthylpyrimidin-2,4(1*H*,3*H*)-dione

nifekalant — 6-[[2-[(2-hidroxietil)[3-(*p*-nitrofenil)propil]amino]etil]amino]-1,3-dimetiluracilo

$C_{19}H_{27}N_5O_5$



nolpitantii besilas

nolpitantium besilate — 1-[2-[(*S*)-3-(3,4-dichlorophenyl)-1-[(*m*-isopropoxyphenyl)acetyl]-3-piperidyl]ethyl-4-phenylquinuclidinium benzenesulfonate

bésilate de nolpitantium — benzènesulfonate de 1-[2-[(3*S*)-3-(3,4-dichlorophényl)-1-[2-[3-(1-méthyléthoxy)phényl]acétyl]pipéridin-3-yl]éthyl]-4-phényl-1-azoniabicyclo[2.2.2]octane

besilato de nolpitantio — bencenosulfonato de 1-[2-[(*S*)-3-(3,4-diclorofenil)-1-[(*m*-isopropoxifenil)acetil]-3-piperidil]etil-4-fenilquinuclidinio

$C_{43}H_{50}Cl_2N_2O_5S$



orbofibanum

orbofiban — *N*-[[(3*S*)-1-(*p*-amidinophenyl)-2-oxo-3-pyrrolidinyl]carbamoyl]-β-alanine, ethyl ester

orbofiban — 3-[3-[(3*S*)-1-(4-carbamimidoylphényl)-2-oxopyrrolidin-3-yl]uréido]propanoate d'éthyle

orbofibán — éster etílico de la *N*-[[(3*S*)-1-(*p*-amidinofenil)-2-oxo-3-pirrolidinil]carbamoil]-β-alanina

$C_{17}H_{23}N_5O_4$



pranazepidum

pranazepide — (-)-*N*-[(*S*)-1-(*o*-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo=[3,2,1-*jk*][1,4]benzodiazepin-3-yl]indole-2-carboxamide

pranazépide — (-)-*N*-[(3*S*)-1-(2-fluorophényl)-4-oxo-3,4,6,7-tétrahydropyrrolo=[3,2,1-*jk*][1,4]benzodiazépin-3-yl]-1*H*-indole-2-carboxamide

pranazepida — (-)-*N*-[(*S*)-1-(*o*-fluorofenil)-3,4,6,7-tetrahidro-4-oxopirrolo=[3,2,1-*jk*][1,4]benzodiazepin-3-il]indol-2-carboxamida

$C_{26}H_{19}FN_4O_2$



rizatriptanum

rizatriptan 3-[2-(dimethylamino)ethyl]-5-(1*H*-1,2,4-triazol-1-ylmethyl)indole

rizatriptan *N*,*N*-diméthyl-2-[5-[(1*H*-1,2,4-triazol-1-yl)méthyl]-1*H*-indol-3-yl]éthanamine

rizatriptán 3-[2-(dimetilamino)etil]-5-(1*H*-1,2,4-triazol-1-ilmetil)indol

$C_{15}H_{19}N_5$



saredutantum

saredutant *N*-[(*S*)-β-[2-(4-acetamido-4-phenylpiperidino)ethyl]-3,4-dichlorophenethyl]-*N*-methylbenzamide

sarédutant *N*-[(2*S*)-4-[4-(acétylamino)-4-phénylpipéridin-1-yl]-2-(3,4-dichlorophényl)butyl]-*N*-méthylbenzamide

saredutant *N*-[(*S*)-β-[2-(4-acetamido-4-fenilpiperidino)etil]-3,4-diclorofenetil]-*N*-metilbenzamida

$C_{31}H_{35}Cl_2N_3O_2$



sitafloxacinum

sitafloxacin (-)-7-[(7*S*)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1*R*,2*S*)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

sitafloxacine acide (-)-7-[(7*S*)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1*R*,2*S*)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoléin-3-carboxylique

sitafloxacino ácido (-)-7-[(7*S*)-7-amino-5-azaspiro[2.4]hept-5-il]-8-cloro-6-fluoro-1-[(1*R*,2*S*)-2-fluorociclopropil]-1,4-dihidro-4-oxo-3-quinolinacarboxílico

$C_{19}H_{18}ClF_2N_3O_3$



sulesomabum

sulesomab — immunoglobulin G 1 (mouse monoclonal IMMU-MN3 Fab' fragment γ-chain anti-human NCA-90 granulocyte cell antigen), disulfide with mouse monoclonal IMMU-MN3 light chain

sulésomab — immunoglobuline G 1 (chaîne γ du fragment Fab' de l'anticorps monoclonal de souris IMMU-MN3 anti-antigène de granulocyte humain NCA-90), disulfure avec la chaîne légère de l'anticorps monoclonal de souris IMMU-MN3

sulesomab — inmunoglobulina G 1 (cadena γ del fragmento Fab' del anticuerpo monoclonal de ratón IMMU-MN3 anti-antígeno de granulocito humano NCA-90), disulfuro con la cadena ligera del anticuerpo monoclonal de ratón IMMU-MN3

taltirelinum

taltirelin — (-)-*N*-[[(*S*)-hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl]carbonyl]-L-histidyl-L-prolinamide

taltiréline — (-)-(2*S*)-1-[(2*S*)-3-(1*H*-imidazol-4-yl)-2-[[[(4*S*)-1-méthyl-2,6-dioxohexahydro=pyrimidin-4-yl]carbonyl]amino]propanoyl]pyrrolidine-2-carboxamide

taltirelina — (-)-*N*-[[(*S*)-hexahidro-1-metil-2,6-dioxo-4-pirimidinil]carbonil]-L-histidil-L-prolinamida

$C_{17}H_{23}N_7O_5$



talviralinum

talviraline — isopropyl (2*S*)-3,4-dihydro-7-methoxy-2-[(methylthio)methyl]-3-thioxo-1(2*H*)-quinoxalinecarboxylate

talviraline — (2*S*)-7-méthoxy-2-[(méthylsulfanyl)méthyl]-3-thioxo-3,4-dihydroquinoxaline-1(2*H*)-carboxylate de 1-méthyléthyle

talviralina

(2*S*)-3,4-dihidro-7-metoxi-2-[(metiltio)metil]-3-tioxo-1(2*H*)-quinoxalinacarboxilato de 1-metiletilo

$C_{15}H_{20}N_2O_3S_2$



technetium (99mTc) pintumomabum

technetium (99mTc) pintumomab

immunoglobulin G 1 (mouse monoclonal 170 γ-chain anti-human adenocarcinoma antigen), disulfide with mouse monoclonal 170 κ-chain, dimer, [99mTc]technetium salt

technétium (99mTc) pintumomab

sel de [99mTc]technétium de l'immunoglobuline G 1 (chaîne γ de l'anticorps monoclonal de souris 170 anti-antigène associé à l'adénocarcinome humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris 170

technetium (99mTc) pintumomab

sal de [99mTc]technetium del inmunoglobulina G 1 (cadena γ del anticuerpo monoclonal de ratón 170 anti-antígeno asociado al adenocarcinoma humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón 170

terbogrelum

terbogrel

(5*E*)-6-[*m*-(3-*tert*-butyl-2-cyanoguanidino)phenyl]-6-(3-pyridyl)-5-hexenoic acid

terbogrel

acide (5*E*)-6-[3-[2-cyano-3-(1,1-diméthyléthyl)guanidino]phényl]-6-(pyrid-3-yl)hex-5-énoïque

terbogrel

ácido (5*E*)-6-[*m*-(3-*terc*-butil-2-cianoguanidino)fenil]-6-(3-piridil)-5-hexenóico

$C_{23}H_{27}N_5O_2$



tresperimusum

tresperimus

[4-[(3-aminopropyl)amino]butyl]carbamic acid, ester with *N*-(6-guanidinohexyl)glycolamide

trespérimus [4-[(3-aminopropyl)amino]butyl]carbamate de 2-[(6-guanidinohexyl)amino]-2-oxoéthyle

tresperimus [4-[(3-aminopropil)amino]butil]carbamato de [(6-guanidinohexil)carbamoil]-metilo

$C_{17}H_{37}N_7O_3$



vinfluninum

vinflunine 4'-deoxy-20',20'-difluoro-8'-norvincaleukoblastine

vinflunine 20',20'-difluoro-4'-désoxy-8'-norvincaleucoblastine

vinflunina 4'-desoxi-20',20'-difluoro-8'-norvincaleucoblastina

$C_{45}H_{54}F_2N_4O_8$

zanamivirum

zanamivir 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-*glycero*-D-*galacto*-non-2-enonic acid

zanamivir acide (4*S*,5*R*,6*R*)-5-(acétylamino)-4-guanidino-6-[(1*R*,2*R*)-1,2,3-trihydroxypropyl]-5,6-dihydro-4*H*-pyrane-2-carboxylique

zanamivir ácido 5-acetamido-2,6-anhidro-3,4,5-tridesoxi-4-guanidino-D-glicero-D-galacto-non-2-enónico

$C_{12}H_{20}N_4O_7$



Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes impaires des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.